Literature DB >> 24184368

Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis.

Amanda A VanDlac1, Nick G Cowan2, Yiyi Chen1, Ross E Anderson1, Michael J Conlin1, Jeffrey C La Rochelle1, Christopher L Amling1, Theresa M Koppie1.   

Abstract

PURPOSE: Patients undergoing radical cystectomy for bladder cancer are at high risk for venous thromboembolism. Recent data have demonstrated that the risk of venous thromboembolism often extends beyond hospital discharge in nonurological surgical populations. To our knowledge the timing of venous thromboembolism in patients who have undergone radical cystectomy during a 30-day postoperative period has not been assessed. Therefore, we evaluated the timing, incidence and risk factors for venous thromboembolism for patients undergoing radical cystectomy for malignancy.
MATERIALS AND METHODS: In this descriptive, observational, retrospective study data from 1,307 patients who underwent radical cystectomy for malignancy from 2005 to 2011 were collected using the American College of Surgeons NSQIP (National Surgical Quality Improvement Program) database. Venous thromboembolism occurrences were evaluated by postoperative day and whether they occurred while an inpatient or after discharge home. Univariate and multivariate Cox regression and logistic regression models were used to evaluate risk factors associated with venous thromboembolism.
RESULTS: Of 1,307 patients 78 (6%) were diagnosed with venous thromboembolism. The mean time to venous thromboembolism diagnosis was 15.2 days postoperatively. Of all venous thromboembolism events 55% were diagnosed after patient discharge home. The 30-day mortality rate from venous thromboembolism was 6.4%. Risk factors for the development of venous thromboembolism on multivariate analysis were age (p = 0.024), operative time (p = 0.004) and sepsis or septic shock (p = 0.0001).
CONCLUSIONS: More than half of all venous thromboembolisms (55%) in patients undergoing radical cystectomy for malignancy occurred after discharge home and the mean time to venous thromboembolism diagnosis was 15.2 days postoperatively. It is reasonable to consider extended duration pharmacological prophylaxis (4 weeks) in this high risk surgical population.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cystectomy; prevention and control; pulmonary embolism; venous thromboembolism; venous thrombosis

Mesh:

Year:  2013        PMID: 24184368     DOI: 10.1016/j.juro.2013.10.096

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

Review 1.  Venous thromboprophylaxis in urological cancer surgery.

Authors:  Wojciech Michalski; Grazyna Poniatowska; Joanna Jonska-Gmyrek; Jakub Kucharz; Pawel Stelmasiak; Karol Nietupski; Katarzyna Ossolinska-Skurczynska; Michal Sobieszczuk; Tomasz Demkow; Pawel Wiechno
Journal:  Med Oncol       Date:  2019-11-25       Impact factor: 3.064

Review 2.  Enhanced recovery programmes for patients undergoing radical cystectomy.

Authors:  Julian Smith; Raj S Pruthi; John McGrath
Journal:  Nat Rev Urol       Date:  2014-07-15       Impact factor: 14.432

3.  Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Vivian S Gainer; Su-Chun Cheng; Tianxi Cai; Elizabeth Scoville; Gauree G Konijeti; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-12       Impact factor: 11.382

4.  Neoadjuvant Platinum-Based Chemotherapy is an Independent Predictor for Preoperative Thromboembolic Events in Bladder Cancer Patients Undergoing Radical Cystectomy.

Authors:  Cliodhna Browne; Niall F Davis; William J Nolan; Eoin D MacCraith; Gerald M Lennon; David W Mulvin; David J Galvin; David M Quinlan
Journal:  Curr Urol       Date:  2017-07-30

5.  Reactive Oxygen Species Signaling Promotes Hypoxia-Inducible Factor 1α Stabilization in Sonic Hedgehog-Driven Cerebellar Progenitor Cell Proliferation.

Authors:  Chad R Potts; M Hope Robinson; Nicholas W Eyrich; Victor Maximov; Anna M Kenney
Journal:  Mol Cell Biol       Date:  2019-04-02       Impact factor: 4.272

6.  Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy.

Authors:  Sumeet Bhanvadia; Kayvan Kazerouni; Soroush T Bazargani; Gus Miranda; Jie Cai; Siamak Daneshmand; Hooman Djaladat
Journal:  World J Urol       Date:  2018-06-06       Impact factor: 4.226

7.  American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Authors:  Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello
Journal:  Blood Adv       Date:  2021-02-23

Review 8.  Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology.

Authors:  Kari A O Tikkinen; Arnav Agarwal; Samantha Craigie; Rufus Cartwright; Michael K Gould; Jari Haukka; Richard Naspro; Giacomo Novara; Per Morten Sandset; Reed A Siemieniuk; Philippe D Violette; Gordon H Guyatt
Journal:  Syst Rev       Date:  2014-12-23

9.  Incidence and risk factors of venous thromboembolism after percutaneous nephrolithotomy: a single-center experience.

Authors:  Huimin Zeng; Meng Gao; Jinbo Chen; Yu Cui; Fang Huang; Feng Zeng; Zhongqing Yang; Yang Li; Zhiyong Chen; Zewu Zhu; Hequn Chen
Journal:  World J Urol       Date:  2021-03-16       Impact factor: 4.226

Review 10.  Contemporary techniques and outcomes of robotic assisted radical cystectomy with intracorporeal urinary diversion.

Authors:  Ardenne S Martin; Anthony T Corcoran
Journal:  Transl Androl Urol       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.